-
1
GLP-1 receptor agonists like semaglutide are essential for diabetes and obesity treatment.
-
2
Significant ION risk associated with higher-dose semaglutide (Wegovy).
-
3
Study analyzed 30 million FDA reports (2017-2024).
-
4
No ION cases reported with oral semaglutide (Rybelsus).
-
5
Monitoring required for men on Wegovy due to increased ION risk.
-
6
No significant ION signal from tirzepatide or other comparators.
-
7
Further prospective studies needed to confirm findings.
Original Source(s)
Related Content
The Missing Piece in the Dark Metabolome Puzzle?
Microdroplets formed during electrospray ionization may trigger chemical reactions that help explain a substantial portion of the “dark metabolome” – though some researchers question their relevance under typical metabolomics conditions
April 8, 2026
-
12 min
FDA Approves First Generic Versions of FARXIGA
Agency approves multiple dapagliflozin generics to reduce heart failure hospitalization risk and improve glycemic control in adults with type 2 diabetes
April 7, 2026
-
2 min
Deprescribing Seen in T2D Care
Researchers examine medication changes in practices with lifestyle medicine access
April 6, 2026
-
3 min
